Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Novel immune checkpoint blockade with ipilimumab, an antibody blocking the cytotoxic T-lymphocyte antigen 4 (CTLA4), is revolutionizing cancer therapy. However, ipilimumab induces symptomatic, sometimes severe, endocrine immune-related adverse events (irAEs) that are inconsistently recognized and reported. The objective of this review was to comprehensively characterize the incidence, presentation, and management of endocrinopathies following ipilimumab therapy in a single center that is highly specialized in immune checkpoint blockade. We carried out a retrospective analysis of endocrine irAEs in melanoma patients receiving ipilimumab therapy in clinical trials between 2007 and 2013. A total of 256 patients were included in this analysis. We reviewed pituitary-, thyroid-, and adrenal-related hormone test results, as well as radiographic studies and the clinical histories of patients, to identify and characterize cases of hypophysitis, hypothyroidism, thyroiditis, and adrenal dysfunction. Following ipilimumab therapy, the overall incidence of hypophysitis was 8% and that of hypothyroidism/thyroiditis 6%. Primary adrenal dysfunction was rare. Therapy with a combination of ipilimumab and nivolumab, an anti-programmed cell death 1 (PDCD1, also called PD1) receptor antibody, was associated with a 22% incidence of either thyroiditis or hypothyroidism and a 9% incidence of hypophysitis. Symptomatic relief, in particular, for hypophysitis, was achieved in all patients with hormone replacement, although endogenous hormone secretion rarely recovered. In summary, we observed that CTLA4 blockade alone, and in particular in combination with PD1 blockade, is associated with an increased risk of symptomatic, sometimes severe, hypophysitis as well as thyroid dysfunction. Prompt initiation with hormone replacement reverses symptoms. Evaluation and reporting of endocrine irAEs in clinical trials should be done using standardized diagnostic criteria and terminology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“novel biological drugs inducing hypophysitis such as ipilimumab or other check-point inhibitors (63).”
From The diagnosis and management of central hypothyroidism in 2018 (2019) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the literature, female gender is described as being a risk factor for ICPi-induced TD, although this is less pronounced than in spontaneous forms [7,46,47] and it is not described in all studies [11,48].”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [46]
Experimental — accuracy not yet measuredIn the citing paper
“the rexinoids (e.g. bexarotene), directly repressing TSHβ expression”
From The diagnosis and management of central hypothyroidism in 2018 (2019) · cites this paper as [63]
In the citing paper
“mitotane, which decreases viability of thyrotrope cells”
From The diagnosis and management of central hypothyroidism in 2018 (2019) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 6×
“The higher overall incidence of hypophysitis in the studies (8%) reviewed compared with that in most of the published trials probably reflects our welldefined clinical, biochemical, and radiographic criteria for identifying cases, which is highly inconsistent and ambiguous in published clinical trials (Hodi et al. 201…”
BackgroundResultInfluentialSelf-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“Nivolumab, a second antibody-derived immune regulator, blocks the activation of the anti-programmed cell death 1 (PDCD1, also called PD1) receptor (Topalian et al. 2012).”
BackgroundAssociation of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175 · cited 2×
“…pituitary hormone secretion. http://erc.endocrinology-journals.org q 2014 Society for Endocrinology DOI: 10.1530/ERC-13-0499 Printed in Great Britain There is a clear association betweenCTLA4 and sporadic, autoimmune thyroid disease in humans and mice (Tomer et al. 2001, Ueda et al. 2003).”
BackgroundInfluentialCTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940 · cited 1×
“The engagement of CTLA4 by its ligands in the B7 co-stimulatory family suppresses T-cell proliferation, helping restore tissue homeostasis (Egen et al. 2002, Pentcheva-Hoang et al. 2004).”
BackgroundCaturegli, P., Newschaffer, C., Olivi, A., Pomper, M. G., Burger, P. C., & Rose, N. R. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0011 · Cited by 588
Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
Lipson, E. J., & Drake, C. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1595 · Cited by 570
B7-1 and B7-2 Selectively Recruit CTLA-4 and CD28 to the Immunological Synapse
Pentcheva-Hoang, T., Egen, J. G., Wojnoonski, K., & Allison, J. P. (2004) · Immunity · doi:10.1016/j.immuni.2004.06.017 · Cited by 436
Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
Corsello, S. M., Barnabei, A., Marchetti, P., De Vecchis, L., Salvatori, R., & Torino, F. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4075 · Cited by 403
Blansfield, J. A., Beck, K. E., Tran, K., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Topalian, S. L., Haworth, L. R., Levy, C., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000178913.41256.06 · Cited by 355
Dillard, T., Yedinak, C. G., Alumkal, J., & Fleseriu, M. (2010) · Pituitary · doi:10.1007/s11102-009-0193-z · Cited by 300
Research works printed but not linked: 1
- 2005, 28, 593
Cited by
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Self-citationSchneider, B. J., Naidoo, J., Santomasso, B. D., Lacchetti, C., Adkins, S., Anadkat, M., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01440 · Cited by 2,372
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
“Pituitary magnetic resonance imaging imaging with gadolinium and selective slides should be considered, searching enlargement or heterogeneity of the gland [40].”
Backgroundon behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,470
Self-citationImmune-related adverse events of checkpoint inhibitors
Ramos-Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suárez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,412
Self-citationA review of cancer immunotherapy toxicity
Kennedy, L. B., & Salama, A. K. S. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21596 · Cited by 1,364
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
Champiat, S., Lambotte, O., Barreau, E., Belkhir, R., Berdelou, A., Carbonnel, F., Cauquil, C., Chanson, P., Collins, M., Durrbach, A., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv623 · Cited by 903
Management of toxicities of immune checkpoint inhibitors
Spain, L., Diem, S., & Larkin, J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.001 · Cited by 854
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review
Friedman, C. F., Proverbs-Singh, T. A., & Postow, M. A. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1051 · Cited by 802
Self-citationCancer immunotherapy—immune checkpoint blockade and associated endocrinopathies.
Byun, D. J., Wolchok, J. D., Rosenberg, L. M., & Girotra, M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.205 · Cited by 685
Self-citationToxicities of Immunotherapy for the Practitioner
Weber, J. S., Yang, J. C., Atkins, M. B., & Disis, M. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0379 · Cited by 650
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
Cortazar, F. B., Marrone, K. A., Troxell, M. L., Ralto, K. M., Hoenig, M. P., Brahmer, J. R., Le, D. T., Lipson, E. J., Glezerman, I. G., Wolchok, J., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.04.008 · Cited by 650
Self-citationIpilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4368 · Cited by 642
Kumar, V., Chaudhary, N., Garg, M., Floudas, C. S., Soni, P., & Chandra, A. B. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00049 · Cited by 627
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0013 · Cited by 570
Self-citationEndocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L.-S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 532
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0012 · Cited by 485
Self-citationFaje, A. T., Sullivan, R., Lawrence, D., Tritos, N. A., Fadden, R., Klibanski, A., & Nachtigall, L. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2306 · Cited by 479
Is autoimmunity the Achilles' heel of cancer immunotherapy?
June, C. H., Warshauer, J. T., & Bluestone, J. A. (2017) · Nature Medicine · doi:10.1038/nm.4321 · Cited by 445
Managing Immune Checkpoint-Blocking Antibody Side Effects
Postow, M. A. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.76 · Cited by 403
Self-citationde Filette, J., Andreescu, C., Cools, F., Bravenboer, B., & Velkeniers, B. (2019) · Hormone and Metabolic Research · doi:10.1055/a-0843-3366 · Cited by 381
Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
Merchant, M. S., Wright, M., Baird, K., Wexler, L. H., Rodriguez-Galindo, C., Bernstein, D., Delbrook, C., Lodish, M., Bishop, R., Wolchok, J. D., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0491 · Cited by 331
Self-citationChaker, L., Razvi, S., Bensenor, I. M., Azizi, F., Pearce, E. N., & Peeters, R. P. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00357-7 · Cited by 330
Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
Faje, A. (2016) · Pituitary · doi:10.1007/s11102-015-0671-4 · Cited by 326
“Patients are typically diagnosed with IH approximately 2–3 months after the initiation of Ipi, though delayed presentations have also been described [46].”
BackgroundSafety of combining radiotherapy with immune-checkpoint inhibition
Hwang, W. L., Pike, L. R. G., Royce, T. J., Mahal, B. A., & Loeffler, J. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0046-7 · Cited by 295
Sznol, M., Postow, M. A., Davies, M. J., Pavlick, A. C., Plimack, E. R., Shaheen, M., Veloski, C., & Robert, C. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.06.002 · Cited by 290
Self-citationDelivanis, D. A., Gustafson, M. P., Bornschlegl, S., Merten, M. M., Kottschade, L., Withers, S., Dietz, A. B., & Ryder, M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00448 · Cited by 278
Self-citationMin, L., Hodi, F. S., Giobbie-Hurder, A., Ott, P. A., Luke, J. J., Donahue, H., Davis, M., Carroll, R. S., & Kaiser, U. B. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2353 · Cited by 274
Walker, M. D., & Shane, E. (2022) · JAMA · doi:10.1001/jama.2022.18331 · Cited by 260
Tirumani, S. H., Ramaiya, N. H., Keraliya, A., Bailey, N. D., Ott, P. A., Hodi, F. S., & Nishino, M. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0102 · Cited by 254
Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events
González-Rodríguez, E., Rodríguez-Abreu, D., & on behalf of the Spanish Group for Cancer Immuno-Biotherapy (GETICA) (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0509 · Cited by 250
Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
de Filette, J., Jansen, Y., Schreuer, M., Everaert, H., Velkeniers, B., Neyns, B., & Bravenboer, B. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2300 · Cited by 244
“Immune checkpoint blockade is associated with a risk for immunerelated adverse events (irAEs) potentially affecting the endocrine organs (2, 3).”
BackgroundImmune-Related Thyroiditis with Immune Checkpoint Inhibitors
Iyer, P. C., Cabanillas, M. E., Waguespack, S. G., Hu, M. I., Thosani, S., Lavis, V. R., Busaidy, N. L., Subudhi, S. K., Diab, A., & Dadu, R. (2018) · Thyroid · doi:10.1089/thy.2018.0116 · Cited by 238
“In a large institutional case series of endocrine irAEs in patients on ipilimumab for the treatment of advanced melanoma, 6/246 patients developed thyroiditis followed by hypothyroidism (8).”
BackgroundImmune checkpoint inhibitor‐related hypophysitis and endocrine dysfunction: clinical review
Joshi, M. N., Whitelaw, B. C., Palomar, M. T. P., Wu, Y., & Carroll, P. V. (2016) · Clinical Endocrinology · doi:10.1111/cen.13063 · Cited by 220
PD-1 Blockade in Advanced Adrenocortical Carcinoma
Raj, N., Zheng, Y., Kelly, V., Katz, S. S., Chou, J., Do, R. K. G., Capanu, M., Zamarin, D., Saltz, L. B., Ariyan, C. E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01586 · Cited by 200
Morganstein, D. L., Lai, Z., Spain, L., Diem, S., Levine, D., Mace, C., Gore, M., & Larkin, J. (2017) · Clinical Endocrinology · doi:10.1111/cen.13297 · Cited by 190
Zhai, Y., Ye, X., Hu, F., Xu, J., Guo, X., Zhuang, Y., & He, J. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0754-2 · Cited by 187
“In this study, we noticed that ipilimumab alone as well as combined with nivolumab showing higher risk of developing hypophysitis compared with other regimens and this trend has also been revealed in another study [41].”
Bastman, J. J., Serracino, H. S., Zhu, Y., Koenig, M. R., Mateescu, V., Sams, S. B., Davies, K. D., Raeburn, C. D., McIntyre, R. C., Haugen, B. R., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4227 · Cited by 181
Endocrine side effects of cancer immunotherapy
Cukier, P., Santini, F. C., Scaranti, M., & Hoff, A. O. (2017) · Endocrine-Related Cancer · doi:10.1530/erc-17-0358 · Cited by 177
Corrections to “Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies”
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw141 · Cited by 177
Self-citationYoest, J. (2017) · ImmunoTargets and Therapy · doi:10.2147/itt.s126227 · Cited by 176
Tan, M. H., Iyengar, R., Mizokami-Stout, K., Yentz, S., MacEachern, M. P., Shen, L. Y., Redman, B., & Gianchandani, R. (2019) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-018-0073-4 · Cited by 172
PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients
Kotwal, A., Kottschade, L., & Ryder, M. (2020) · Thyroid · doi:10.1089/thy.2019.0250 · Cited by 168
Self-citationBurch, H. B. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1901214 · Cited by 164
Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy
Lee, H., Hodi, F. S., Giobbie-Hurder, A., Ott, P. A., Buchbinder, E. I., Haq, R., Tolaney, S., Barroso-Sousa, R., Zhang, K., Donahue, H., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0208 · Cited by 161
“In the same study, the incidence of thyroid disorders was higher (22%) with combination CTLA-4 and PD-1 blockade, even though the incidence of hypophysitis was 9%, similar to that of anti–CTLA-4 monotherapy (11).”
InfluentialAutoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)
Pérez-De-Lis, M., Retamozo, S., Flores-Chávez, A., Kostov, B., Pérez-Álvarez, R., Brito‐Zerón, P., & Ramos‐Casals, M. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1372421 · Cited by 158
Stelmachowska‐Banaś, M., & Czajka-Oraniec, I. (2020) · Endocrine Connections · doi:10.1530/ec-20-0342 · Cited by 151
Scott, E. S., Long, G. V., Guminski, A., Clifton-Bligh, R. J., Menzies, A. M., & Tsang, V. H. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0810 · Cited by 142
French Endocrine Society guidance on endocrine side effects of immunotherapy
Castinetti, F., Albarel, F., Archambeaud, F., Bertherat, J., Bouillet, B., Buffier, P., Briet, C., Cariou, B., Caron, P., Chabre, O., et al. (2019) · Endocrine Related Cancer · doi:10.1530/erc-18-0320 · Cited by 140
Endocrinological side-effects of immune checkpoint inhibitors
Torino, F., Corsello, S. M., & Salvatori, R. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000293 · Cited by 136
Orlov, S., Salari, F., Kashat, L., & Walfish, P. G. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4560 · Cited by 134
“Any patients who had previously received antiCTLA-4 mAb therapy were excluded from this cohort given an increased risk of thyroid dysfunction (5).”
BackgroundMethodInfluentialGirotra, M., Hansen, A. R., Farooki, A., Byun, D. J., Min, L., Creelan, B., Callahan, M. K., Atkins, M. B., Sharon, E., Antonia, S. J., et al. (2018) · JNCI Cancer Spectrum · doi:10.1093/jncics/pky021 · Cited by 132
Self-citationClinical assessment of immune-related adverse events
Sosa, A., Lopez Cadena, E., Simon Olive, C., Karachaliou, N., & Rosell, R. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918764628 · Cited by 132
Kim, H. I., Kim, M., Lee, S.-H., Park, S. Y., Kim, Y. N., Kim, H., Jeon, M. J., Kim, T. Y., Kim, S. W., Kim, W. B., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1375642 · Cited by 123
Thyroid disorders induced by checkpoint inhibitors
Ferrari, S. M., Fallahi, P., Galetta, F., Citi, E., Benvenga, S., & Antonelli, A. (2018) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-018-9463-2 · Cited by 123
Alexander, W. (2016) · PubMed Central · Cited by 121
Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review
Garutti, M., Lambertini, M., & Puglisi, F. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100276 · Cited by 119
Kähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Mössner, R., Ugurel, S., Zimmer, L., Gutzmer, R., & for the “Cutaneous Side Effects” Committee of the Work Group Dermatological Oncology (ADO) (2016) · JDDG: Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13047 · Cited by 118
Jain, D., Russell, R. R., Schwartz, R. G., Panjrath, G. S., & Aronow, W. S. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0846-x · Cited by 114
Novel immune check point inhibiting antibodies in cancer therapy—Opportunities and challenges
Diesendruck, Y., & Benhar, I. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.02.001 · Cited by 114
Barroso‐Sousa, R., Ott, P. A., Hodi, F. S., Kaiser, U. B., Tolaney, S. M., & Min, L. (2018) · Cancer · doi:10.1002/cncr.31200 · Cited by 113
New insight in endocrine-related adverse events associated to immune checkpoint blockade
Elia, G., Ferrari, S. M., Galdiero, M. R., Ragusa, F., Paparo, S. R., Ruffilli, I., Varricchi, G., Fallahi, P., & Antonelli, A. (2019) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2019.101370 · Cited by 113
Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management
Astaras, C., Micheli, R. D., Moura, B. G., Hundsberger, T., & Hottinger, A. F. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0810-1 · Cited by 112
Toxicity management of immunotherapy for patients with metastatic melanoma
Linardou, H., & Gogas, H. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.07.10 · Cited by 111
Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy
Liu, Y., Zang, X.-Y., Wang, J., Huang, S., Jiang, X., & Zhang, P. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109437 · Cited by 111
Autoimmune endocrine dysfunctions associated with cancer immunotherapies
Ferrari, S. M., Fallahi, P., Elia, G., Ragusa, F., Ruffilli, I., Patrizio, A., Galdiero, M. R., Baldini, E., Ulisse, S., Marone, G., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102560 · Cited by 107
Immune‐Related Adverse Events From Immune Checkpoint Inhibitors
Marrone, K. A., Ying, W., & Naidoo, J. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.394 · Cited by 106
Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms
Fessas, P., Possamai, L. A., Clark, J., Daniels, E., Gudd, C., Mullish, B. H., Alexander, J. L., & Pinato, D. J. (2020) · Immunology · doi:10.1111/imm.13141 · Cited by 105
Anti–PD-L1 Treatment Induced Central Diabetes Insipidus
Zhao, C. N., Tella, S. H., Rivero, J. D., Kommalapati, A., Ebenuwa, I., Gulley, J. L., Strauss, J., & Brownell, I. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01905 · Cited by 105
Johnson, D. B., Friedman, D. L., Berry, E., Decker, I., Ye, F., Zhao, S., Morgans, A. K., Puzanov, I., Sosman, J. A., & Lovly, C. M. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0217 · Cited by 101
“Third, we provided additional support for the chronic nature of ipilimumab-induced endocrinopathies (13, 29).”
BackgroundEvolving molecularly targeted therapies for advanced-stage thyroid cancers
Bible, K. C., & Ryder, M. M. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.19 · Cited by 101
Self-citationNano-immunotherapy: Unique mechanisms of nanomaterials in synergizing cancer immunotherapy
Liu, Q., Duo, Y., Fu, J., Qiu, M., Sun, Z., Adah, D., Kang, J., Xie, Z., Fan, T., Bao, S., et al. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101023 · Cited by 99
MANAGEMENT OF ENDOCRINE DISEASE: Immune check point inhibitors-induced hypophysitis
Albarel, F., Castinetti, F., & Brue, T. C. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0169 · Cited by 98
Kotwal, A., Gustafson, M. P., Bornschlegl, S., Kottschade, L., Delivanis, D. A., Dietz, A. B., Gandhi, M., & Ryder, M. (2020) · Thyroid · doi:10.1089/thy.2020.0075 · Cited by 94
Self-citationAcute Hyperglycemia Associated with Anti-Cancer Medication
Hwangbo, Y., & Lee, E. K. (2017) · Endocrinology and Metabolism · doi:10.3803/enm.2017.32.1.23 · Cited by 94
Thyroid-Like Ophthalmopathy in a Euthyroid Patient Receiving Ipilimumab
McElnea, E., Ní Mhéalóid, Á., Moran, S., Kelly, R., & Fulcher, T. (2014) · Orbit · doi:10.3109/01676830.2014.949792 · Cited by 93
Exercise medicine for advanced prostate cancer
Hart, N. H., Galvao, D. A., & Newton, R. U. (2017) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000276 · Cited by 91
Savoia, P., Astrua, C., & Fava, P. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1129478 · Cited by 90
Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?
Lemiale, V., Meert, A., Vincent, F., Darmon, M., Bauer, P. R., de Louw, A. V., & Azoulay, É. (2019) · Annals of Intensive Care · doi:10.1186/s13613-019-0487-x · Cited by 90
Thyroid dysfunctions secondary to cancer immunotherapy
Chalan, P., Dalmazi, G. D., Pani, F., Remigis, A. D., Corsello, A., & Caturegli, P. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0778-8 · Cited by 89
Quirk, S. K., Shure, A. K., & Agrawal, D. K. (2015) · Translational research · doi:10.1016/j.trsl.2015.06.005 · Cited by 86
Hryniewicki, A. T., Wang, C., Shatsky, R. A., & Coyne, C. J. (2018) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2018.07.005 · Cited by 83
How we treat endocrine complications of immune checkpoint inhibitors
Paschou, S. Α., Stefanaki, K., Ψαλτοπούλου, Θ., Liontos, M., Koutsoukos, K., Zagouri, F., Lambrinoudaki, I. V., & Dimopoulos, M. A. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100011 · Cited by 81
Rivero, J. D., Cordes, L. M., Kłubo-Gwieździńska, J., Madan, R. A., Nieman, L. K., & Gulley, J. L. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0470 · Cited by 81
Leveraging the immune system to treat advanced thyroid cancers
French, J. D., Bible, K. C., Spitzweg, C., Haugen, B. R., & Ryder, M. M. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30277-7 · Cited by 81
Self-citationRuggeri, R. M., Campennì, A., Giuffrida, G., Trimboli, P., Giovanella, L., Trimarchi, F., & Cannavò, S. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0984-z · Cited by 76
Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach
Iglesias, P. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.08.019 · Cited by 72
Sagiv, O., Kandl, T. J., Thakar, S. D., Thuro, B. A., Busaidy, N. L., Cabanillas, M., Jimenez, C., Dadu, R., Graham, P. H., Debnam, J. M., et al. (2019) · Ophthalmic Plastic & Reconstructive Surgery · doi:10.1097/iop.0000000000001161 · Cited by 71
“Hypothyroidism or thyroiditis was previously reported in different studies in 6% to 15% of patients treated with ipilimumab monotherapy or in combination with nivolumab.(9,10) Orbital inflammation related to TED was reported in 3 patients treated with ipilimumab.”
ResultInsights into non-classic and emerging causes of hypopituitarism
Prodam, F., Caputo, M., Mele, C., Marzullo, P., & Aimaretti, G. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00437-2 · Cited by 71
Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity
Inno, A., Metro, G., Bironzo, P., Grimaldi, A. M., Grego, E., Nunno, V. D., Picasso, V., Massari, F., & Gori, S. (2017) · Tumori Journal · doi:10.5301/tj.5000625 · Cited by 71
A review of serious adverse effects under treatment with checkpoint inhibitors
Heinzerling, L., & Goldinger, S. M. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000358 · Cited by 70
Ma, C., Hodi, F. S., Giobbie‐Hurder, A., Wang, X., Zhou, J., Zhang, A., Zhou, Y., Mao, F., Angell, T. E., Andrews, C., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0613 · Cited by 69
Heaney, A. P., Sumerel, B., Rajalingam, R., Bergsneider, M., Yong, W. H., & Liau, L. M. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2702 · Cited by 68
Emergency presentations in patients treated with immune checkpoint inhibitors
Cooksley, T., Gupta, A., Al-Sayed, T., & Lorigan, P. C. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.025 · Cited by 68
Herrmann, S. M., Abudayyeh, A., Gupta, S., Gudsoorkar, P., Klomjit, N., Motwani, S. S., Karam, S., Costa E Silva, V. T., Khalid, S. B., Anand, S., et al. (2025) · Kidney international · doi:10.1016/j.kint.2024.09.017 · Cited by 67
Thyroid-related adverse events induced by immune checkpoint inhibitors
Chera, A., Stancu, A. L., & Bucur, O. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1010279 · Cited by 67
Percik, R., Shlomai, G., Tirosh, A., Tirosh, A., Leibowitz‐Amit, R., Eshet, Y., Greenberg, G., Merlinsky, A., Barhod, E., Steinberg‐Silman, Y., et al. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102454 · Cited by 67
Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook
Gopalakrishnan, D., Koshkin, V. S., Ornstein, M. C., Papatsoris, A., & Grivas, P. D. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s158753 · Cited by 66
Anticancer Therapy-Induced Atrial Fibrillation: Electrophysiology and Related Mechanisms
Yang, X., Li, X., Yuan, M., Tian, C., Yang, Y., Wang, X., Zhang, X., Sun, Y., He, T., Han, S., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01058 · Cited by 66
Metadata
- Authors
- Ryder, M., Callahan, M., Postow, M. A., Wolchok, J., & Fagin, J. A.
- Affiliations
- Mayo Clinic (US)
- Weill Cornell Medicine (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Ryder, Mabel
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2014-04
- Volume
- 21
- Issue
- 2
- Pages
- 371-381
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- PMC
- PMC4573438
- OpenAlex
- W2166107256
- Cited by
- 439
- References
- 14
- Citations by year
- 2026: 12 · 2025: 20 · 2024: 23 · 2023: 21 · 2022: 32 · 2021: 44 · 2020: 49 · 2019: 55 · 2018: 53 · 2017: 56 · 2016: 44 · 2015: 25 · 2014: 5
- FWCI
- 20.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrine Related Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bristol-Myers Squibb
- GlaxoSmithKline
- National Cancer Institute (K08CA133183, P50CA172012, P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- ipilimumab, immune-related adverse events, CTLA-4 blockade, immune checkpoint inhibitors, advanced melanoma, hypophysitis, hypothyroidism, thyroiditis, adrenal dysfunction, nivolumab, anti-PD-1 therapy, hormone replacement therapy, endocrine toxicity
- MeSH terms
- Ipilimumab, Antibodies, Monoclonal, Antineoplastic Agents, Endocrine System Diseases, Humans, Melanoma, Skin Neoplasms, Testosterone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.